Comparison of subcutaneous and intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor for peripheral blood stem cell mobilization

A. Kessinger, M. R. Bishop, J. R. Anderson, J. O. Armitage, P. J. Bierman, E. C. Reed, S. Tarantolo, M. A. Tempero, J. M. Vose, P. I. Warkentin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In an effort to determine whether subcutaneous or continuous intravenous infusion administration of rhGM-CSF results in better hematopoietic progenitor mobilization, the findings of two sequential clinical trials were reviewed. Patients who had received prior chemotherapy for leukemia, lymphoma, multiple myeloma, breast cancer, or other solid tumors and were candidates for high-dose therapy received rhGM-CSF, 250 μg/m2/day, either as a continuous intravenous infusion (trial 1) or subcutaneously (trial 2) for stem cell mobilization. At least five apheresis collection procedures were performed to collect a target number of 6.5 x 108 mononuclear cells (MNC)/kg. For the 37 patients in trial 1, the collections contained a median of 7.99 x 108 MNC/L (range 6.42-21.36) and a median of 5.27 x 104 CFU- GM/Kg (range 0.28-19.35). In trial 1, 25 patients were autografted with their cells and recovered 0.5 x 109 granulocytes/L at a median of 12 days (range 6-16). For the 33 patients in trial 2, the autograft product contained a median of 7.63 x 108 MNC/kg (range 6.51-22.66) and 6.31 x 104 CFU-GM/kg (range 0.06-60.4). In trial 2, 25 patients were autografted. The median time to reach 0.5 x 109 granulocytes/L was 11 days (range 9-26). All patients received rhGM-CSF after peripheral stem cell transplant. No significant differences in the collected products or the time to hematopoietic recovery was found between the two trials (p > 0.05). The mobilization effects of subcutaneous rhGM-CSF in these pretreated patients were similar to those of intravenous rhGM-CSF.

Original languageEnglish (US)
Pages (from-to)81-84
Number of pages4
JournalJournal of hematotherapy
Volume4
Issue number2
DOIs
StatePublished - Jan 1 1995

Fingerprint

Hematopoietic Stem Cell Mobilization
Granulocyte-Macrophage Colony-Stimulating Factor
Intravenous Administration
Granulocyte-Macrophage Progenitor Cells
Granulocytes
Intravenous Infusions
Blood Component Removal
Autografts
Peripheral Blood Stem Cells
Multiple Myeloma
Lymphoma
Leukemia
Clinical Trials
Breast Neoplasms
Transplants
Drug Therapy

ASJC Scopus subject areas

  • Immunology
  • Hematology

Cite this

@article{73164cd738aa4d808a1e6a8b7d786d03,
title = "Comparison of subcutaneous and intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor for peripheral blood stem cell mobilization",
abstract = "In an effort to determine whether subcutaneous or continuous intravenous infusion administration of rhGM-CSF results in better hematopoietic progenitor mobilization, the findings of two sequential clinical trials were reviewed. Patients who had received prior chemotherapy for leukemia, lymphoma, multiple myeloma, breast cancer, or other solid tumors and were candidates for high-dose therapy received rhGM-CSF, 250 μg/m2/day, either as a continuous intravenous infusion (trial 1) or subcutaneously (trial 2) for stem cell mobilization. At least five apheresis collection procedures were performed to collect a target number of 6.5 x 108 mononuclear cells (MNC)/kg. For the 37 patients in trial 1, the collections contained a median of 7.99 x 108 MNC/L (range 6.42-21.36) and a median of 5.27 x 104 CFU- GM/Kg (range 0.28-19.35). In trial 1, 25 patients were autografted with their cells and recovered 0.5 x 109 granulocytes/L at a median of 12 days (range 6-16). For the 33 patients in trial 2, the autograft product contained a median of 7.63 x 108 MNC/kg (range 6.51-22.66) and 6.31 x 104 CFU-GM/kg (range 0.06-60.4). In trial 2, 25 patients were autografted. The median time to reach 0.5 x 109 granulocytes/L was 11 days (range 9-26). All patients received rhGM-CSF after peripheral stem cell transplant. No significant differences in the collected products or the time to hematopoietic recovery was found between the two trials (p > 0.05). The mobilization effects of subcutaneous rhGM-CSF in these pretreated patients were similar to those of intravenous rhGM-CSF.",
author = "A. Kessinger and Bishop, {M. R.} and Anderson, {J. R.} and Armitage, {J. O.} and Bierman, {P. J.} and Reed, {E. C.} and S. Tarantolo and Tempero, {M. A.} and Vose, {J. M.} and Warkentin, {P. I.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1089/scd.1.1995.4.81",
language = "English (US)",
volume = "4",
pages = "81--84",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Comparison of subcutaneous and intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor for peripheral blood stem cell mobilization

AU - Kessinger, A.

AU - Bishop, M. R.

AU - Anderson, J. R.

AU - Armitage, J. O.

AU - Bierman, P. J.

AU - Reed, E. C.

AU - Tarantolo, S.

AU - Tempero, M. A.

AU - Vose, J. M.

AU - Warkentin, P. I.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - In an effort to determine whether subcutaneous or continuous intravenous infusion administration of rhGM-CSF results in better hematopoietic progenitor mobilization, the findings of two sequential clinical trials were reviewed. Patients who had received prior chemotherapy for leukemia, lymphoma, multiple myeloma, breast cancer, or other solid tumors and were candidates for high-dose therapy received rhGM-CSF, 250 μg/m2/day, either as a continuous intravenous infusion (trial 1) or subcutaneously (trial 2) for stem cell mobilization. At least five apheresis collection procedures were performed to collect a target number of 6.5 x 108 mononuclear cells (MNC)/kg. For the 37 patients in trial 1, the collections contained a median of 7.99 x 108 MNC/L (range 6.42-21.36) and a median of 5.27 x 104 CFU- GM/Kg (range 0.28-19.35). In trial 1, 25 patients were autografted with their cells and recovered 0.5 x 109 granulocytes/L at a median of 12 days (range 6-16). For the 33 patients in trial 2, the autograft product contained a median of 7.63 x 108 MNC/kg (range 6.51-22.66) and 6.31 x 104 CFU-GM/kg (range 0.06-60.4). In trial 2, 25 patients were autografted. The median time to reach 0.5 x 109 granulocytes/L was 11 days (range 9-26). All patients received rhGM-CSF after peripheral stem cell transplant. No significant differences in the collected products or the time to hematopoietic recovery was found between the two trials (p > 0.05). The mobilization effects of subcutaneous rhGM-CSF in these pretreated patients were similar to those of intravenous rhGM-CSF.

AB - In an effort to determine whether subcutaneous or continuous intravenous infusion administration of rhGM-CSF results in better hematopoietic progenitor mobilization, the findings of two sequential clinical trials were reviewed. Patients who had received prior chemotherapy for leukemia, lymphoma, multiple myeloma, breast cancer, or other solid tumors and were candidates for high-dose therapy received rhGM-CSF, 250 μg/m2/day, either as a continuous intravenous infusion (trial 1) or subcutaneously (trial 2) for stem cell mobilization. At least five apheresis collection procedures were performed to collect a target number of 6.5 x 108 mononuclear cells (MNC)/kg. For the 37 patients in trial 1, the collections contained a median of 7.99 x 108 MNC/L (range 6.42-21.36) and a median of 5.27 x 104 CFU- GM/Kg (range 0.28-19.35). In trial 1, 25 patients were autografted with their cells and recovered 0.5 x 109 granulocytes/L at a median of 12 days (range 6-16). For the 33 patients in trial 2, the autograft product contained a median of 7.63 x 108 MNC/kg (range 6.51-22.66) and 6.31 x 104 CFU-GM/kg (range 0.06-60.4). In trial 2, 25 patients were autografted. The median time to reach 0.5 x 109 granulocytes/L was 11 days (range 9-26). All patients received rhGM-CSF after peripheral stem cell transplant. No significant differences in the collected products or the time to hematopoietic recovery was found between the two trials (p > 0.05). The mobilization effects of subcutaneous rhGM-CSF in these pretreated patients were similar to those of intravenous rhGM-CSF.

UR - http://www.scopus.com/inward/record.url?scp=0029124772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029124772&partnerID=8YFLogxK

U2 - 10.1089/scd.1.1995.4.81

DO - 10.1089/scd.1.1995.4.81

M3 - Article

C2 - 7543352

AN - SCOPUS:0029124772

VL - 4

SP - 81

EP - 84

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 2

ER -